Table 2 The Common Metastatic Signature
Number of studies repeated | Up-regulated in metastasis | Down-regulated in metastasis | Â | Â | Â |
|---|---|---|---|---|---|
4 studies | Not significant | ACTG2 | GJA1 | NBL1 | RARRES1 |
| Â | Â | CASP7 | GNG12 | PAGE4 | SELE |
| Â | Â | CSRP1 | GSN | PAM | SLC12A4 |
| Â | Â | CYR61 | IER2 | PCP4 | SMTN |
| Â | Â | DPT | ISL1 | PDE4D | SORBS1 |
| Â | Â | DSTN | JMJD3 | PIGB | SYNPO2 |
| Â | Â | FILIP1L | JUNB | PKIG | TCF21 |
| Â | Â | FLNC | KRT15 | PLA2G2A | TMEM49 |
| Â | Â | FOSB | LUM | PLEKHC1 | TPM1 |
| Â | Â | FUCA1 | MAPK1 | PPP1R12A | TSC22D1 |
| Â | Â | GADD45B | MFAP4 | RAP1A | VCL |
5 studies | EZH2 | ACTA2 | DKFZP564O0823 | LMOD1 | RBPMS |
| Â | Â | BMPR1A | DMN | MCL1 | SPARCL1 |
| Â | Â | CAMK2G | FBLN1 | MGP | SPG20 |
| Â | Â | CCND2 | FHL1 | NR4A1 | TACC1 |
| Â | Â | CNN1 | FXYD3 | NR4A3 | TAGLN |
| Â | Â | CTGF | HBEGF | PPP1R12B | ZFP36 |
| Â | Â | DIO2 | KCNMA1 | PYROXD1 | Â |
6 studies | None | BTG2 | KCNMB1 | MYLK | Â |
| Â | Â | JUND | MYH11 | SOD3 | Â |
8 studies | None | TPM2 | Â | Â | Â |